Alkaline glycine

Phase 2Small molecule

IIndiana University

Alkaline glycine is one of 4 small molecule programs targeting Nitric Oxide. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nitric OxideEnrolling by invitation

Nitric OxidePhase 2

Enrolling by invitation

Competition

Competitive Landscape

4 competitors in Nitric Oxide

#DrugCompanyPhaseTrials

Inomax

MMallinckrodt

Phase 2

13 2

Alkaline glycine

IIndiana University

Phase 2

1 3

Ino

UUniversity of Colorado, Denver

Preclinical

1 4

L-NAME

UUniversity of Georgia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nitric Oxide1 trial

Determining Airway pH by Compartmental Exhaled Nitric Oxide Levels During Alkaline Buffer Challenge

Enrolling by invitation·IIndiana University·Phase 2·NCT04738422·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alkaline glycine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alkaline glycine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alkaline glycine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIndiana University

Alkaline glycine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nitric Oxide1 trial

References

Drug Info

Quick Facts

Related News